APGE
Apogee Therapeutics, Inc.
135.10$
+0.0%
vs. previous close
Closing price · As of: Sep 3, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -5.9% | +105.2% | -2.8% | -3.0% | -2.9% | -5.3% | -7.9% | -4.8% | +49.7% | +38.0% | +3.3% | |
| – | -6.6% | +106.0% | -16.9% | -21.6% | -0.9% | -1.5% | -1.0% | +4.6% | +37.3% | +44.8% | -7.6% | |
| – | -37.2% | +310.3% | -36.7% | -61.3% | +19.4% | -24.6% | +16.2% | -13.1% | +21.9% | +243.4% | -76.6% | |
| – | -6.5% | +106.4% | -17.1% | -22.2% | -1.0% | -1.4% | -1.5% | +4.3% | +38.5% | +45.2% | -8.3% | |
| – | – | – | – | – | -1.6% | +6.7% | -17.5% | +8.3% | +33.1% | +22.1% | – | |
| – | +25.1% | +3.2% | +21.8% | +55.0% | -11.3% | +9.8% | -6.0% | +3.8% | -16.5% | +13.9% | +273.0% | |
| – | +19.7% | +4.8% | +14.2% | +32.5% | -12.4% | +15.4% | -4.3% | +7.9% | -18.0% | +18.1% | +13.8% | |
| – | – | +3.6% | +47.4% | +70.5% | +12.8% | +22.9% | +1.2% | +1.3% | -14.1% | -10.4% | -24.6% | |
| – | +77.4% | +100.7% | +28.5% | -59.9% | -51.7% | +128.3% | +132.2% | -93.4% | +224.7% | +1.3% | +149.0% | |
| – | -7.2% | +111.0% | -3.5% | -5.1% | -2.4% | -6.1% | -8.0% | -5.3% | +54.2% | +38.9% | -4.9% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | 0.0% | -0.9% | +12.6% | +0.5% | -2.8% | +5.4% | +0.4% | +0.6% | +3.3% | +14.8% | +8.3% |
Data as of: September 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.